Join MySLAS Social



SLAS2021 Call for Abstracts Now Open

SLAS2021 Goes Digital

Celebrate 10 years of laboratory automation, scientific education and innovation.
January 25 – 27, 2021
Live and on demand from anywhere!

Join us from home, the lab, your office or your preferred knowledge-consuming and networking spot!

SLAS2021 Digital promises to bring you quality life sciences programming and the latest product
and technology innovations you’ve come to expect – with a digital twist.



This year’s program will feature more than 80 scientific talks, 45 vendor presentations and two inspiring keynotes.
Take in content live or on demand as your schedule allows.

Sponsor or exhibit.

There will still be plenty of opportunities for you to showcase your product, service and company through impactful and attention-getting sponsor and exhibitor opportunities. We’ll be announcing New Product Awards too!
A complete Digital Sponsorship and Exhibitor Prospectus will be available in late-September.


The SLAS2021 Call for Abstracts is now open. Ignite your research by presenting a live talk or poster from the comfort of your own home. You can even wear pajama pants — who will know?!


While registration isn’t available until October, full details on this year’s pricing is.
The best part? SLAS Premier Members attend for FREE!

Startups and emerging companies: Apply to be on Innovation AveNEW

SLAS’s opportunities for collaboration and recognition are unique.

Join the SLAS2021 email list.

SLAS2021 Digital Program Chairs: Amy Kallmerten (Merck) and Louis Scampavia (Scripps Research Florida)

SLAS2021 Call for Abstracts Now Open

SLAS2021 Digital Registration Information

SLAS is excited to be going digital together. We look forward to welcoming an extended global life sciences community to this online event to Ignite Science!

Registration will open in early October.

SLAS2021 Digital access is included with SLAS premier membership. What does this mean? If your dues are paid through the 2021 calendar year, or if you’re a student, this event is FREE for you to attend.

Category Registration Fee
SLAS Member (Paid through Dec. 31, 2021) $0.00 (FREE)
SLAS Non-Member $249.00 (with option to join)
Students (undergraduate, graduate, post-doc) $0.00 (FREE)

Members include Premier, Early-Career Professional, Retired and our new Lab Level membership (you’ll be hearing more about that very soon!)

We’ll keep you informed of the details regarding SLAS2021 Digital over the coming months, and we can tell you now that it will include:

  • 80+ Scientific Talks
  • 3 Short Course Workshops
  • 2 Keynote Presenters
  • Live and On-Demand Virtual Exhibition
  • Solutions Spotlight (exhibitor presentations)
  • Education and Content from Exhibitors
  • $10,000 Innovation Award
  • New Product Awards
  • Innovation AveNEW & SLAS Ignite Award
  • Tony B. Academic Awards
  • Give-a-Ways and Games
  • Global Time Zone-compatible Schedule of Events

SLAS2021 Call for Abstracts Now Open


Ignite 2021 with a Spark

While the format for the 10th Annual SLAS International Conference and Exhibition is different for 2021, the program will include the same high-quality scientific discovery, technology and innovation research attendees have come to expect over the last decade.

SLAS2021 Digital will feature more than 80 scientific talks from 10 educational tracks and 45 vendor tutorials to ignite virtual discussions and brainstorming. SLAS2021 Digital will also feature keynote speakers Deborah Sliptez, Ph.D., (Merck) and Atul Butte, M.D., Ph.D., (University of California Health System), both of whom will deliver impactful and relevant presentations on topics sure to get you excited about the future of drug discovery and automation technology.

Log in live or take in content on-demand as your schedule allows.

Ignite your research. Submit a poster or podium abstract today!

SLAS2021 Scientific Podium Program

Podium presentations at SLAS2021 are organized into ten educational tracks. Track and session titles and descriptions and names of track chairs and session chairs follow below.

The Scientific Program Committee selects speakers based on the innovation, relevance and applicability of research. If your proposed topic does not squarely fit into the focus of one of these tracks, please submit it for committee consideration regardless. The committee members use their judgment and experience to select presentations that best address the interests and priorities of today’s life sciences discovery and technology community.

Podium abstracts will be assessed in September and the podium program will be finalized and published by late-October.

Submit an Abstract

Track Chairs: Andreas Luippold, Ph.D., Boehringer-Ingelheim and Paul Tesar, Ph.D., Case Western Reserve University

The qualitative and quantitative characterization of endogenous and exogenous analytes in biological systems are the basis of drug discovery and development. This track will highlight important developments in bioanalytical technologies, including advances in label-free technologies, applications of target and mechanism deconvolution techniques and ‘omics approaches to biomarker analysis. Planned sessions include:

Label-Free Bioanalytical Techniques
Session Chair: Frank Buettner, Ph.D., Boehringer Ingelheim

Target Engagement and Pathways
Session Chair: Kilian Huber, Ph.D., University of Oxford

Target and Mechanism Deconvolution After Phenotypic Screens
Session Chair: Paul Tesar, Ph.D., Case Western Reserve University

Track Chairs: Melissa Crisp, Ph.D., Eli Lilly and Amy Quinn, Ph.D., GlaxoSmithKline

This track will focus on recent innovations across the assay development and screening field, including the adoption of novel technologies and intelligent informatics approaches, to enable the implementation of effective screening campaigns and hit triage strategies to identify, validate and characterize potential leads. Attendees will hear about the development of robust, physiologically relevant biochemical, biophysical and cellular assays that are crucial for identifying active ligands that engage their targets directly. There will be an emphasis on recent case studies where cutting-edge assay approaches to improve the success rates of screening have been coupled with next-generation therapeutic modalities and novel mechanisms of action to broaden the scope of target classes that can be drugged. Planned sessions include:

Advanced Imaging and High-Content Assays
Session Chair: Regis Doyonnas, Ph.D., Pfizer

Applications of CRISPR Technology in Drug Discovery
Session Chair: Davide Gianni, Ph.D., AstraZeneca

Biochemical & Biophysical Assays
Session Chair: Larry Szewczuk, Ph.D., Janssen Pharmaceuticals

DNA-Encoded Libraries
Session Chair: Patrick McEnaney, Ph.D., Haystack Sciences

In vitro Immunological Assays
Session Chair: Amy Quinn, Ph.D., GlaxoSmithKline

Chemical Biology
Session Chair: Christopher Parker, Ph.D., Scripps Research

Track Chairs: Helen Plant, AstraZeneca and James Pilling, M.S., AstraZeneca

This track focuses on the innovative use of biological or chemistry applications, tools, technologies, and techniques as they pertain to automated high throughput screening, the advancement of laboratory processes or improvement of the quality and impact of experimental laboratory data. Emphasis is placed on advancements in chemically and biologically relevant technologies using engineering, analytical, informatics, and application to cutting edge automation-assisted research. Planned sessions include:

Screening & Profiling at Higher-Throughput Using Physiologically Relevant Cell Models
Session Chair: Sylvia Boj, Ph.D., Hubrecht Organoid Technology

Technologies to Bridge the Gap Between High-Content and High-Throughput
Session Chair: James Pilling, M.S., AstraZeneca

Automating Screening Processes
Session Chair: Steven van Helden, Ph.D., Pivot Park Screening Centre

Automating Chemistry in the Age of AI
Session Chair: Lee Cronin, Ph.D., University of Glasgow

Microtiter Plates and Beyond: High-Throughput Miniaturization While Maintaining Physiological Relevance
Session Chair: Lorena Kallal, Ph.D., GlaxoSmithKline

In-house and Open Source Automation: Products, devices and software used to support laboratory automation
Session Chair: Pierre Baillargeon, M.S., Scripps Research

Track Chairs: Jason Ekert, Ph.D., GlaxoSmithKline and Marie-Claire Peakman, Ph.D., Pfizer

Attendees will learn from industry and academic leaders about new cellular technologies and their application in the understanding of normal physiology and disease, and in the generation of disease-relevant models for drug discovery and pre-clinical development. The track will cover models used for illuminating functional genomics and for pharmacology, ADME or toxicity outcomes. The technologies covered will include the generation and use of patient-derived models, iPSC models, complex co-cultures, organoids, organ-on-chips and microphysiologic models. The track will also include cellular therapeutics and cell technologies to support biologics and gene therapy approaches. Of particular interest will be the therapeutic areas of oncology, infectious diseases, immunology and rare diseases. Planned sessions include:

Novel and Innovative Applications of Cellular Technologies
Session Chair: Chris Hughes, Ph.D., Aracari Biosciences

Application of Disease-Relevant Cellular Models in Drug Discovery and Pre-Clinical Development
Session Chair: Marie-Claire Peakman, Ph.D., Pfizer

Development and Evaluation of Cellular Therapeutics
Session Chair: Sandra Santulli-Marotto, Ph.D., Bristol Myers Squibb

Track Chairs: Nicola Richmond, Ph.D., GlaxoSmithKline and Marti Head, Ph.D., Oakridge National Lab

The world is rapidly transforming. Data are ambient and exist in volumes far exceeding the quantities imagined by the pioneers of our fields. As data volume and complexity continue to grow exponentially, so does the demand for tools that can rise to the occasion. Gone are the days of my data and your data. Analyzing single or even multiple sets of similar data will not yield the breakthroughs of the past but alongside the challenges are new opportunities for technology to empower discovery. This session will focus on the rapidly evolving role of digital technology and scientific information management as well as the hardware and software of the modern digital research lab. Emphasis will be placed on transforming data feeds from instruments into scientific understanding, particularly with the use of artificial intelligence and with additional consideration for distributed laboratories and the use of the cloud in the data ecosystem as we live through a global pandemic. Planned sessions include:

Lab of the Future
Session Chair: John Williams, Ph.D., Neurocrine

Building a Data Ecosystem
Session Chair: Marti Head, Ph.D., Oakridge National Lab

The Age of AI in the Lab
Session Chair: Joe Jacobson, Ph.D., MIT/DeepCure

Track Chairs: Tim Wigle, Ph.D., Ribon Therapeutics and Allison Olszewski, Ph.D., Civetta Therapeutics

Creating the next generation of small molecule drugs calls for novel drug target strategies. This track will provide assay and screening scientists with cutting edge information on technologies and methodologies that enable them to advance chemical matter for clinically relevant pharmacologies. Planned sessions include:

Drugging the Undruggable
Session Chair: Allison Olszewski, Ph.D., Civetta Therapeutics

Advances in Protein Homeostasis
Session Chair: Eunice Park, Ph.D., C4 Therapeutics

Targeting RNA Regulation
Session Chair: Tim Wigle, Ph.D., Ribon Therapeutics

Track Chairs: Elodie Sollier-Christen, Ph.D., Vortex Biosciences and Claire Hur, Ph.D., Johns Hopkins University

Freeman Dyson famously said "when we make a new tool, we see a new cosmos". Micro and nano-scale tools have accelerated the pace of scientific discovery, particularly in next-generation sequencing, single cell analysis, analytical chemistry, high throughput screening and point-of-care diagnostics. These tools leverage unique physics at small length scales, the ability to interact and interrogate biological systems at similar length scales and the ability to massively parallelize assays. Attendees will be given a broad overview of such emerging tools and their applications from both industry and academic leaders. This year's track will highlight advances in single-cell analysis technologies, infectious disease theragnostics, and personalized medicine. Planned sessions include:

Microfluidic-Based Profiling of Eukaryotic and Microbial Cells at Single-Cell Resolution
Session Chair: Hee-Sun Han, Ph.D., University of Illinois

Disposable Near-Patient Testings for Infectious Disease
Session Chair: Nicolas Durand, Ph.D., Abionic

The emerging role of micro/nano innovations for personalized medicine
Session Chair: Soojung Hur, Ph.D., Johns Hopkins University

Track Chairs: Yasmina Abdiche, Ph.D., Immunoprecise and Andrew Bradbury, Ph.D., Specifica

Planned sessions include:

Therapeutic Antibody Fragments
Session Chair: Andrew Bradbury, Ph.D., Specifica

Alternate Scaffolds with Clinical Potential
Session Chair: Yasmina Abdiche, Ph.D., Immunoprecise

Silencing Diseases at the Genetic Level Using siRNA
Session Chair: Karol Watson, M.D., Ph.D., UCLA Program in Preventive Cardiology

Track Chairs: Martin Giera, Ph.D., Leiden University Medical Center and Baljit Ubhi, Ph.D., Sciex

'Omics technologies have become an inevitable part of drug research. While much attention has been put on (chemical)-proteomics have other 'omics-technologies yet received less awareness. In this track we will put the spotlight on metabolomics, transcriptomics and glycomics as upcoming techniques for drug research and biologics characterization. Planned sessions include:

Metabolomics in Drug Research
Session Chair: Baljit Uhbi, Ph.D., Sciex

Session Chair: Valeria Orlova, Ph.D., Leiden University Medical Center

Sweetening the Pot: Recent Advances in the Characterization of Biotherapeutic Glycoproteins
Session Chair: Guinevere Lageveen-Kammeijer, Leiden University Medical Center

Track Chairs: John Joslin, Ph.D., Genomics Institute of the Novartis Research Foundation and Nichol Miller, Ph.D., Pfizer

The Precision Medicine for Drug Discovery track focuses on approaches that aim to resolve disease complexity. This includes molecular, biochemical, bioengineering and bioinformatic strategies in disease biology, diagnostics, screening and translational medicine. The session will emphasize the application of state-of-the-art, quantitative, high-throughput and high-resolution approaches to both cellular models and complex tissues. These strategies enable multiparametric computational analyses to reveal the complex interplay of genetics, cell types and drugs to advance precision medicine. Topics include improvements in stem cell-based disease modeling, bioengineering, molecular and cellular assay and bioinformatic approaches. Planned sessions include:

Closing the Gap Between Assay and Patient
Session Chair: Stephane Richard, Ph.D., Oncodesign

Applications of Single-Cell Analysis to Disease Studies
Session Chair: Nichol Miller, Ph.D., Pfizer

Session Chair: Kate Hastie, Ph.D., La Jolla Institute for Immunology

SLAS2021 Call for Abstracts Now Open

Ignite Your Research

Submit your research for presentation and award consideration at SLAS2021 Digital.

Scientists, engineers, academics, and business leaders from academia, government and industry are invited to submit podium and poster abstracts in a wide range of cutting-edge educational tracks. Contributions from graduate students, post-doctoral associates and junior faculty are highly encouraged.

Emerging companies and organizations: Submit your new product or service for the opportunity to be placed within Innovation AveNEW and to compete for the highly-coveted New Product Award. Innovation AveNEW participants may also compete for the SLAS Ignite Award which includes a $5,000 cash prize.

Submit an Abstract


Podium Abstract Submissions Due:

Monday, September 14, 2020

Innovation Award Submission Deadline:

Monday, September 14, 2020

Tony B. Academic Travel Award Podium Submissions Due:

Monday, September 14, 2020

Tony B. Academic Travel Award Poster Submissions Due:

Monday, October 5, 2020

Podium Abstract Decisions Communicated:

Monday, October 12, 2020

Innovation AveNEW Application Deadline:

Monday, October 12, 2020

Poster Abstract Submissions Due:

Monday, October 19, 2020
(Deadline for inclusion in Student Poster Competition)

Monday, January 11, 2021
(Final Poster Abstract Submission Deadline)

Poster Abstract Decisions Communicated:

Beginning October 28, 2020
(On a monthly basis thereafter through Final Deadline.)

SLAS Ignite Award Opt-In Deadline:

Monday, November 23, 2020

New Product Award Application Deadline:

Monday, January 4, 2021

SLAS Innovation Award

Learn more about the SLAS Innovation Award, a $10,000 cash prize recognizing the extraordinary work behind one unique and special podium presentation.


SLAS Tony B. Travel Awards Program

The Tony B. Academic Award Program is an exclusive opportunity for presenters to get additional funding for the SLAS International Conference and Exhibition. Students, graduate students, postdoctoral associates and junior faculty are encouraged to apply. Click here for complete details on the Tony B. Academic Award program.


Student Poster Award

The SLAS Student Poster Award recognizes innovative research by students, graduate students, post-doctoral associates and junior faculty (less than four years in first academic appointment) who are chosen to present a poster during SLAS2021. The Top 3 winners will receive a cash award of $500 each!


SLAS Ignite Award

The SLAS Ignite Award recognizes the best start-up or emerging company exhibiting within Innovation AveNEW.

Companies selected for Innovation AveNEW, and who opt-in to compete for the SLAS Ignite Award, will be judged by an SLAS panel on a combination of key concepts, including their marketing plan, market presence and potential; funding prospects; plan for growth and the existence of balanced company leadership, among other qualities.


New Product Award

Gain extra recognition for your company’s new product or service by entering the SLAS New Product Award competition. This is the perfect opportunity to showcase your product through invaluable publicity and visibility.

To simplify your submission process, make sure to have all of your materials together prior to submitting your abstract. Screenshots of each step in the abstract process will be viewed by using the 'Guidelines' section of the submission site.

To submit, the following documents are needed:

  • Abstract title
  • Abstract text (450-word limit)
  • Presentation preference: podium, poster or both (if applicable)
  • Identify applicable track (preference only)
  • Primary presenter details (one per abstract); Name, Job Title, Organization, Address, City, State, Postal Code, Country, Email, Business Phone, Biography
  • Award nominations (if applicable)
  • Identify co-authors: Name, Job Title, Organization, City, State, Country, Email


General Instructions:

  • Abstracts relevant to any of the SLAS2021 tracks are requested and will be reviewed by the SLAS2021 Scientific Program Committee. View a complete list and brief description of all SLAS2021 tracks.
  • Authors are invited to submit abstracts describing original research on topics relevant to any of the seven program tracks for either poster or podium presentation. Abstracts should describe work not previously the subject of a podium presentation and address why the work is novel. Importantly, the abstract should clearly present the research itself and the results that have been obtained. Abstracts will be assessed according to the novelty of the work with an emphasis to abstracts that clearly detail results.
  • Podium presentations are 30 minutes in length including questions and answers.
  • Poster presentations will be scheduled during the Poster Lightning Talk on Wednesday, January 27.
  • Note regarding the $10,000 SLAS Innovation Award: The SLAS Innovation Award judging process is extensive and requires the panel of judges to review and evaluate hundreds of scientific abstract submissions. To ensure your abstract receives optimal consideration, please include information on methods, results and conclusions.
  • The primary presenter will serve as the primary contact for SLAS and must have a valid email address.
  • All abstracts must be submitted electronically via this online abstract submission system.
  • The body of the abstract may not exceed 450 words.
  • The title is considered separate from the body of the abstract and is not included in the word limit. Specific formatting requirements are included on the submission form.
  • It is suggested that you first develop your abstract in a word processing program then copy and paste the information in the appropriate section. There is no spell or grammar check function in the online submission process. Please do not use all capital letters in your abstract or title.
  • If accepted, your abstract will be published EXACTLY as it has been entered into the system. This includes company names, presenter names, etc. Submissions will not be edited in any way prior to publishing in conference materials.
  • Fields denoted with asterisks (*) are required fields.
  • To learn more about the various SLAS Awards presented at the conference and learn if you are eligible to apply, please visit the following links:
  • At the close of the application submission period, all abstracts will be reviewed by the SLAS2021 Scientific Program Committee to determine which abstracts are accepted into the program. The SLAS2021 Scientific Program Committee reserves the right to accept abstracts into tracks other than the one selected by the submitter during the submission process.
  • Those submitted as podium abstracts but not accepted for the podium program will be reviewed for a poster submission if indicated as such by the submitter during the submission process.
  • Podium presentation confirmations will be distributed on Monday, October 12, 2020.


Sample Abstract

To view a sample abstract, which adheres to these guidelines, please click here.


Abstract Acceptance and Notification

  • A member of the SLAS Professional Team will contact all selected abstract submitters with information regarding scheduling, speaker agreements, and the Speaker Resource Center. Speakers agree to use the Speaker Resource Center as the primary source for communicating speaker information.
  • It is expected all speakers will adhere to policies and deadlines established to ensure accurate and timely information to SLAS members.
  • Primary Presenters are responsible for communicating with co-authors regarding acceptance or rejection, deadlines and all other submission details.
  • Whenever possible SLAS will record presentations and make those recordings available to members and participants. In some cases, webcasting or streaming of sessions may be offered as well. All speakers will be required to provide SLAS with the permission to record, broadcast, edit, transcribe, archive, duplicate, distribute, reproduce and sell any written or visual material submitted in connection with presentations at this SLAS conference in any media now existing or developed in the future.
  • SLAS presenters are required to electronically agree to the speaker guidelines and releases using the button below.
  • Accepted poster presentations will be required to physically present the poster during a two-hour time slot as indicated in the acceptance notification.
  • Presentation confirmations will be distributed according to the approximate timeline below:
    • Podium Presentation Confirmation: Monday, October 12, 2020
    • Tony B. Application Confirmations: Monday, October 12, 2020
    • Poster Presentation Confirmations: Beginning October 28, 2020, on a monthly basis through January 11, 2021


Speaker’s Agreement

Selected speakers must agree to the following:

  1. LOGISTICS. I shall provide my Presentation live at the event on the dates, at the times, and at the location specified by SLAS. SLAS is entitled to contemporaneously make my Presentation available in real-time via the internet or other medium to online or remote Presentation attendees.
  2. MATERIALS. In connection with my Presentation, I shall provide SLAS with my PowerPoint, photograph, biographical information, and Presentation abstract (“Materials”) by the date, in the format, and in the manner specified by SLAS. I hereby grant SLAS a worldwide, sub-licensable, irrevocable, non-exclusive, royalty-free right and license (but not the obligation) to reproduce, prepare derivative works based on, distribute, perform publicly, display publicly, and otherwise use and exploit my Materials, for all purposes, including advertising in all media now known or hereafter created, in connection with: (i) promoting the Event and my Presentation; (ii) SLAS’s online learning management system; and (iii) reporting on the Event.
  3. PUBLICITY RELEASE. I hereby grant SLAS a worldwide, sub-licensable, irrevocable, non-exclusive, royalty-free right and license (but not the obligation) to use my name, photograph, image, likeness, and voice, including composite or modified representations, for all purposes, including advertising in all media now known or hereafter created, in connection with: (i) promoting the Event, my Presentation; (ii) SLAS’s online learning management system; and (iii) reporting on the Event.
  4. RECORDINGS. I hereby grant SLAS a worldwide, sub-licensable, irrevocable, exclusive, royalty-free right and license (but not the obligation) to photograph, record and film, in film, audio-video, audio-only, or any other media now known or hereafter created, me and my Presentation at the Event (“Recordings”). SLAS is the exclusive owner of the Recordings and has the exclusive right to reproduce, prepare derivative works based on, distribute, perform publicly, display publicly, transfer, license, and otherwise use and exploit the Recordings. SLAS will not retain digital or print copies of any materials beyond SLAS’s Recordings. SLAS shall not include SLAS’s recording of my entire Presentation or my Materials in SLAS’s online learning management system (which allows members of the public to access and view presentation recordings and materials) without my written permission. If I give my written permission to SLAS to include my Presentation and Materials on SLAS’s online learning management system (“OLMS License”), SLAS will list my Presentation in the OLMS and include it as a reference for future SLAS coursework/education.
  5. RETAINED RIGHTS. I hereby retain all rights in my Presentation, my Materials, and my name, photograph, image, likeness, and voice not licensed to SLAS under this Agreement, including my underlying ownership of my Presentation and my Materials.
  6. INSPECTION AND APPROVAL WAIVER. I hereby waive any right to inspect or approve any use of my Materials, the Recordings, and my name, photograph, image, likeness, and voice, by SLAS, contemplated by this Agreement.
  7. NO FINANCIAL COMPENSATION. Except as otherwise stated in the speaker resource center, I am not entitled to receive any financial compensation as consideration for this Agreement or the rights granted to SLAS hereunder. I have no right to share in any proceeds enjoyed by SLAS, derived from SLAS’s exploitation of the rights granted to SLAS under this Agreement.
  8. REPRESENTATIONS AND WARRANTIES. In addition to any other representations and warranties made by me in this Agreement, I represent and warrant that: (i) I am over the age of 18; (ii) I have all of the legal rights necessary to enter into, perform my obligations under, and grant SLAS the rights stated in this Agreement; (iii) my entering into, performing my obligations under, and granting SLAS the rights stated in this Agreement does not violate applicable law or the rights of any third-party; (iv) my Presentation and Materials will not promote specific goods, services, commercial interests, or my personal business or financial interests; (v) my Presentation and Materials will not contain profanity or content that is defamatory, abusive, harassing, violent, or hateful; (vi) my Presentation and Materials will not denigrate or promote discrimination against any individual or groups of individuals based on their race, color, religion, creed, national origin, ancestry, ethnicity, sex, gender (including gender nonconformity and status as a transgender or transsexual individual), age, physical or mental disability, citizenship, military status, or political affiliation; and (vii) I shall comply with all Event venue’s and SLAS’s policies, procedures, rules, guidelines, and directions applicable to my Event participation, Presentation, and Materials. I agree to defend, indemnify, and hold harmless SLAS and its directors, officers, employees, volunteers, agents, representatives, contractors, and affiliates from and against all claims by third parties relating to my breach or alleged breach of this Agreement, including or any of the foregoing representations and warranties.
  9. CANCELLATION. SLAS is entitled to cancel my Presentation and Event participation at any time by notifying me of its decision to do so. If I am unable to provide my Presentation at the Event for any reason, I shall notify SLAS as soon as possible.
  10. WAIVER OF CLAIMS AND LIMITATION OF LIABILITY. To the fullest extent permitted by applicable law, I hereby irrevocably waive all legal and equitable rights relating to all liabilities, claims, demands, actions, suits, damages, and expenses of any kind, including claims for copyright or trademark infringement, defamation, invasion of any rights of privacy, violation of rights of publicity, physical or emotional injury or distress, or any similar claims or causes of action in tort, contract, equity, or any other legal theory, now known or hereafter known in any jurisdiction throughout the world (“Claims”), I may have directly or indirectly against SLAS and any of its directors, officers, employees, volunteers, agents, representatives, contractors, and affiliates (collectively, “Released Persons”) related to: (i) my Event participation, Presentation, Materials, name, photograph, image, likeness, and voice; (ii) the Recordings; and/or (iii) SLAS’s use and exploitation of the rights granted to SLAS under this Agreement. I covenant not to make or bring any Claims against SLAS and the other Released Persons and forever release and Discharge SLAS and the other Released Person from liability under all Claims.
  11. RELATIONSHIP OF THE PARTIES. This Agreement creates an independent contractor relationship between me and SLAS. This Agreement does not create any other kind of legal relationship between me and SLAS. I am not entitled to contract for or bind SLAS.
  12. GOVERNING LAW, CHOICE OF FORUM, JURY TRIAL WAIVER. The laws of the State of Illinois, excluding its choice of law rules, govern this Agreement and the federal laws of the United States. A party shall institute any action related to this Agreement in the United States District Court for the Northern District of Illinois, or the Illinois state courts located in DuPage County, Illinois. The parties irrevocably submit to the exclusive jurisdiction of these courts. Each party hereby waives, to the extent permitted by applicable law, any right to a trial by jury, in any action between the parties related to this Agreement.
  13. MISCELLANEOUS. This Agreement inures to the benefit of, and is binding on, the parties and their heirs, executors, administrators, legal representatives, successors, and permitted assigns. If there is a conflict between the headings or section numbers and the text of this Agreement, the text controls. No inference, presumption, or conclusion is to be drawn against a party because that party or its directors, officers, employees, volunteers, agents, representatives, contractors, or affiliates drafted all or any part of this Agreement. If a court having jurisdiction over a dispute between the parties, determines any portion of this Agreement is unenforceable, the rest of this Agreement remains in effect to the extent permitted by applicable law. Upon a determination that any portion of this Agreement is unenforceable, it is the desire of the parties that the court modifies this Agreement to effect the original intent of the parties as closely as possible in order that the transaction contemplated by this Agreement may be consummated as originally contemplated to the greatest extent possible under applicable law. Provisions in this Agreement, which, by their nature, should apply beyond the termination or conclusion of this Agreement, remain in force after this Agreement’s termination or conclusion. No amendment to this Agreement is valid unless in writing and signed by both parties.
  14. ENTIRE AGREEMENT. This Agreement states the entire agreement between the parties regarding the subject matter of this Agreement, and supersedes all prior negotiations, understandings, and agreements (oral or written) between the parties, regarding the subject matter of this Agreement.

All presenters must be registered as full conference participants. Limited funds may be available to assist with travel and/or hotel funding. These funds are based on availability and financial need. Contact Meghan Schofield at for more information.

All poster presenters must be registered as full conference unless you are registered as an SLAS exhibitor.

SLAS2021 Call for Abstracts Now Open

Event Contacts

Society for Laboratory Automation and Screening
1301 West 22nd Street, Suite 708
Oak Brook, IL 60523
+1.877.990.SLAS (7527) — US Toll Free
+1.630.256.SLAS (7527) — International
+1.866.208.0291 — fax



Chief Executive Officer:
Vicki Loise, CMP, CAE

Director, Global Events:
Amy Wilkinson, CMP

Scientific Director:
Mike Tarselli, PhD

Program Manager:
Elizabeth Frank

Director, Marketing Communications:
Jill Hronek

Senior Membership Manager:
Mary Geismann

Speaker and Short Course Coordinator:
Meghan Schofield